Philips Showcases AI and Platform-Driven Innovation at 93rd CMEF

At the 93rd China International Medical Equipment Fair (CMEF), Royal Philips showcased over 50 innovative products and platform-based solutions centered on “AI and Platform-Driven Innovation” with seven core zones: the Precision Diagnosis Hub, Interventional Navigation Pod, Critical Care Station, Respiratory & Sleep Station, Personal Health Circle, Innovation Service Station, and Innovation Future Lab. Among them, 20 products are deeply empowered by artificial intelligence (AI), covering the entire diagnosis, treatment, and prognosis management pathway for high-prevalence diseases in China, including cardiovascular, neurological, oncological, and sleep respiratory conditions.

Liu Ling, President of Philips Greater China, stated that China’s healthcare sector is at a critical juncture toward value-driven innovation. From prevalent diseases to rare diseases, and from acute critical care to chronic disease management, numerous unmet needs remain in diagnosis and treatment pathways. What is needed is no longer just breakthroughs in point technologies, but a systematic transformation of diagnostic and therapeutic models. Philips is committed to a clinical-value-driven approach, deeply integrating AI with platform-based innovation, and collaborating with clinical and industrial partners to advance smart healthcare, ensuring that more “China Firsts” become “China Benefits for All” and lead global progress.

Philips views AI as a key driver for reshaping the future of healthcare. During this year’s CMEF, Philips debuted the “Innovation Future Lab,” a dedicated zone showcasing forward-looking solutions scheduled for market launch over the next three years, clearly mapping the path from research and development innovation to clinical application. Among the major launches, the globally debuted Innovation AI3 Super Brain Platform embeds AI throughout the entire magnetic resonance imaging workflow, transforming high-definition imaging into a value-added digital asset for hospitals and providing robust evidence-based support for clinical research and drug efficacy evaluation. The China-debuted Azurion S AI-empowered Universal Smart Cathlab achieves 0.1 millisecond posture adjustment, reduces radiation dose by up to 83 percent, and improves surgical efficiency by 17 percent, redefining diagnostic and interventional standards with an open, integrated artificial intelligence ecosystem. Another highlight, the EPIQ CVx Transcend, features eight cardiovascular-specific artificial intelligence tools that standardize and automate complex assessments. The China-debuted Deep CT leverages clinical artificial intelligence imaging to deliver high-definition, low-dose, high-efficiency, full-field low-noise thin-slice images, empowering primary care diagnostic capabilities. Additionally, the Visual Simulation Avatar uses three-dimensional animation to intuitively present real-time changes in patient physiological parameters, capturing the equivalent of 10 seconds of traditional information in just 3 seconds, thereby enhancing clinical team situational awareness and enabling faster, more accurate identification of changes in critical care scenarios. Philips also announced a significant upgrade to its China innovation strategy, partnering with local clinical and industrial partners to build a smart, collaborative, and sustainable innovation ecosystem, helping China’s healthcare industry move toward a new stage of higher-quality development.

Focusing on the full spectrum of high-prevalence diseases, Philips has deeply addressed unmet clinical needs in cardiovascular disease, oncology, neurodegenerative disorders, and rare and complex diseases. The specially designed “One-Stop Brain-Heart Center” at this year’s CMEF booth provides a panoramic view of a fully closed-loop management solution integrating imaging, artificial intelligence, and smart connectivity, covering early screening and warning, precision diagnosis, efficient treatment, and long-term follow-up. As medical imaging enters a new phase of “structure-metabolism” synergistic analysis, Philips unveiled the world’s first Metabolic CT, Meta CT, moving beyond traditional structural diagnosis into metabolic characterization. This provides critical technical support for early tumor screening and precise identification of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, buying valuable time for early diagnosis and treatment. The artificial intelligence-powered simulation positioning CT, Rembra RT, developed at Philips’ Shenyang Innovation Center, manufactured in Suzhou, and exported to global markets, can handle complex radiotherapy scenarios and exemplifies Philips’ local innovation strength. In ultrasound, Philips China-debuted the Elevate series ultrasound systems, built on a new imaging platform, technologies, and probes, delivering more realistic images to physicians and providing solutions with both clinical and research value. Furthermore, as a health technology company spanning professional healthcare and personal health, Philips also showcased the DreamStation home non-invasive respiratory intelligent solution, providing comfortable ventilation therapy for sleep apnea patients at home.

Guided by its “2030 Impact Vision,” Philips is committed to driving healthcare systems toward greater resilience through technological innovation and sustainable practices. The BlueSeal helium-free magnetic resonance imaging system demonstrated at this CMEF significantly reduces device dependence on scarce helium resources, lowering the environmental impact across the device lifecycle while minimizing downtime risks due to resource supply fluctuations, thereby improving equipment utilization and enhancing healthcare system operational resilience. With a significantly reduced overall weight, the magnetic resonance imaging system offers more flexible installation and deployment, no longer confined to specific spaces, further improving access to high-quality imaging services. Leveraging CMEF as a key industry platform, Philips will further deepen collaborative innovation with healthcare institutions, research universities, and industrial partners, promoting the deep integration of industry, academia, research, and application, and accelerating the translation of innovative technologies into clinical and primary care settings to benefit broader populations.